Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Seliciclib (Primary)
- Indications Cushing syndrome
- Focus Proof of concept; Therapeutic Use
- 30 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 30 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 11 Jan 2016 According to Cyclacel Pharmaceuticals media release, the company expects to report data from this trial in 2016.